ACOT11 and malignant colon neoplasm: STARD14 was revealed to harbor heterogeneous roles in different tumors: on the one hand, STARD14 is downregulated in clear cell renal cell carcinoma and colon cancer and considered as a protective biomarker for tumorigenesis 31, 32; on the other hand, STARD14 expression is higher in NSCLC and associated with poor prognosis in LUSC patients 33.